Breaking News
Start for Free 0
🥇 First rule of investing? Know when to save! Up to 55% off Investing Pro before BLACK FRIDAY
CLAIM SALE
Close

DexCom Inc (DXCM)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
65.58 +1.85    +2.90%
09/11 - Closed. Currency in EUR
Type:  Equity
Market:  Germany
ISIN:  US2521311074 
S/N:  A0D9T1
  • Volume: 561
  • Bid/Ask: 65.15 / 65.49
  • Day's Range: 63.72 - 66.07
DexCom 65.58 +1.85 +2.90%

DexCom Company Profile

 
Explore the DexCom company profile for core details about DexCom, assess DexCom company details, including a description of the company, key contact information, and insights into the top executives. Discover the company's operations and leadership to better understand its role in the industry.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

7550

Equity Type

ORD

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Contact Information

Address 6340 Sequence Drive
San Diego, 92121
United States
Phone 858 200 0200
Fax -

Top Executives

Name Age Since Title
Kevin Ronald Sayer 64 2007 Executive Chairman, CEO & President
Eric J. Topol 70 2009 Independent Director
Nicholas Augustinos 65 2009 Independent Director
Mark G. Foletta 63 2014 Lead Independent Director
Bridgette P. Heller 63 2019 Independent Director
Steven R. Altman 63 2013 Independent Director
Kyle Malady 56 2020 Independent Director
Richard A. Collins 67 2017 Independent Director
Karen M. Dahut 60 2020 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

DXCM Comments

Write your thoughts about Dexcom Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Chirag Chopra
Chirag Chopra Feb 22, 2023 23:12
Saved. See Saved Items.
This comment has already been saved in your Saved Items
who is here after apple
tapas halder
tapas halder Feb 22, 2023 23:12
Saved. See Saved Items.
This comment has already been saved in your Saved Items
after Apple???
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email